ATNM
Actinium Pharmaceuticals Inc
$
1.720
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.790
Open
1.790
VWAP
--
Vol
189.33K
Mkt Cap
53.66M
Low
1.700
Amount
--
EV/EBITDA(TTM)
--
Total Shares
29.78M
EV
-9.47M
EV/OCF(TTM)
--
P/S(TTM)
--
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Show More
3 Analyst Rating
248.84% Upside
Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
248.84% Upside
Current: 1.720
Low
4.00
Averages
6.00
High
9.00
248.84% Upside
Current: 1.720
Low
4.00
Averages
6.00
High
9.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-04-01
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-27
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-27
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-25
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-25
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-20
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-18
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-11
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-11
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Actinium Pharmaceuticals Inc (ATNM.A) is -1.66, compared to its 5-year average forward P/E of -5.36. For a more detailed relative valuation and DCF analysis to assess Actinium Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.36
Current PE
-1.66
Overvalued PE
-2.55
Undervalued PE
-8.18
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.13
Current EV/EBITDA
0.15
Overvalued EV/EBITDA
-0.33
Undervalued EV/EBITDA
-3.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
222.69
Current PS
0.00
Overvalued PS
659.68
Undervalued PS
-214.31
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
+73.37%
-16.64M
Operating Profit
FY2025Q1
YoY :
+83.83%
-15.94M
Net Income after Tax
FY2025Q1
YoY :
+64.52%
-0.51
EPS - Diluted
FY2025Q1
YoY :
+2.56%
-7.57M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATNM News & Events
Events Timeline
2025-06-23 (ET)
2025-06-23
11:40:33
Actinium highlights expanded data set for ATNM-400 in prostate cancer
2025-05-06 (ET)
2025-05-06
08:47:08
Actinium enrolls first patient on the trial studying Iomab-ACT
2025-04-28 (ET)
2025-04-28
08:35:57
Actinium Pharmaceuticals' ATNM-400 shows efficacy in prostate cancer study
Sign Up For More Events
Sign Up For More Events
News
4.0
06-24BenzingaHC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target
9.0
06-23NewsfilterActinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
1.0
06-13NewsfilterLife Sciences Investor Forum: Now Available for Online Viewing
Sign Up For More News
People Also Watch
DWSN
Dawson Geophysical Co
1.490
USD
+5.67%
DHAI
DIH Holding US Inc
0.270
USD
+0.74%
SGRP
SPAR Group Inc
1.140
USD
-0.87%
SCYX
SCYNEXIS Inc
0.733
USD
+0.41%
ESLA
Estrella Immunopharma Inc
0.920
USD
+1.10%
SER
Serina Therapeutics Inc
5.715
USD
+5.83%
OPXS
Optex Systems Holdings Inc
12.460
USD
+2.89%
VNCE
Vince Holding Corp
1.600
USD
+3.90%
KTCC
Key Tronic Corp
3.040
USD
+1.00%
FAQ
What is Actinium Pharmaceuticals Inc (ATNM) stock price today?
The current price of ATNM is 1.72 USD — it has decreased -3.91 % in the last trading day.
What is Actinium Pharmaceuticals Inc (ATNM)'s business?
What is the price predicton of ATNM Stock?
What is Actinium Pharmaceuticals Inc (ATNM)'s revenue for the last quarter?
What is Actinium Pharmaceuticals Inc (ATNM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Actinium Pharmaceuticals Inc (ATNM)'s fundamentals?
How many employees does Actinium Pharmaceuticals Inc (ATNM). have?